These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Intraperitoneal chemotherapy through implantable injection port in patients with advanced ovarian (or tubal) carcinoma]. Ryuko K; Iwanari O; Moriyama M; Moriyama M; Nakayama S; Miyako J; Kitao M Gan To Kagaku Ryoho; 1991 Aug; 18(11):2052-7. PubMed ID: 1877848 [TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal chemotherapy comes of age. Cannistra SA N Engl J Med; 2006 Jan; 354(1):77-9. PubMed ID: 16394306 [No Abstract] [Full Text] [Related]
11. Re: "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study". Markman M Gynecol Oncol; 2007 Apr; 105(1):279-80; author reply 280-1. PubMed ID: 17291570 [No Abstract] [Full Text] [Related]
12. [A case of stage IVb ovarian carcinoma successfully treated with intra-arterial infusion chemotherapy using implantable reservoir system]. Kobayashi O; Kuwae C; Kohyama A; Yorinaga Y; Sudo H; Kitada H; Otsuka H; Minami T Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1697-700. PubMed ID: 1530335 [TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166 [No Abstract] [Full Text] [Related]
15. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740 [TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer. Kotz KW; Schilder RJ Semin Oncol; 1995 Jun; 22(3):250-62. PubMed ID: 7777869 [No Abstract] [Full Text] [Related]
17. [Ovarian carcinoma: various aspects of intraperitoneal chemotherapy]. Los G; Beijnen JH; Dubbelman R; ten Bokkel Huinink WW; McVie JG Ned Tijdschr Geneeskd; 1988 Jul; 132(29):1347-50. PubMed ID: 3412503 [No Abstract] [Full Text] [Related]
18. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist]. Sugiyama T; Yoshizaki A; Hatayama S Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537 [TBL] [Abstract][Full Text] [Related]
19. Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Petru E; Benedicic Ch; Huell A Gynecol Oncol; 2006 Jul; 102(1):129; author reply 130. PubMed ID: 16600354 [No Abstract] [Full Text] [Related]
20. Intraperitoneal therapy for ovarian cancer: why has it not become standard? Rowan K J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952 [No Abstract] [Full Text] [Related] [Next] [New Search]